Client: Dignify Therapeutics       Location: Research Triangle Park, North Carolina
Sector: Therapeutics       Link: dignifytherapeutics.com


Since its founding in 2012, Dignify Therapeutics has been on a mission to address the unmet medical needs of individuals with bladder and bowel disorders caused by spinal injuries. Tackling an area often overlooked by larger pharmaceutical companies due to its perceived lack of profitability, Dignify aims to develop innovative therapies that enable urination and defecation on demand. Their work not only enhances the quality of life for many but also has the potential to reduce healthcare costs significantly.

 

I can’t stress enough that once you have multiple concurrent awards, you need a partner who knows the regulatory, accounting, and compliance requirements to guide you and keep you on track. Having a group like EGC at your side as you leverage non-dilutive funding to advance your science is indispensable.

Ed Burgard, Ph.D., Co-Founder and President


For the past decade, EGC has been proud to support Dignify with grant writing assistance and ongoing accounting and compliance services. Thanks to EGC’s guidance, Dignify established a non-dilutive funding strategy which has driven >10 years of consistent NIH funding. Over this time, Dignify has successfully secured more than $20 million in non-dilutive grant funding. We look forward to seeing Dignify’s continued growth and impact!

$20M

Non-dilutive funding awarded

+10

Years as EGC client


Timeline

2012

  • Founded

2015

  • Dignify Therapeutics’ Chief Scientific Officer invited to participate at CURE-UAB

2016

  • Dignify Therapeutics Receives $3.1 million in NIH Awards for Bladder, Bowel Therapy

2017

  • Dignify Therapeutics receives additional $4.1 million in NIH Awards for Bladder and Bowel Therapy

2018

  • Dignify Therapeutics Announces the Issuance of US Patent No. 10,086,034 for treatment of voiding dysfunction

2019

  • Dignify Therapeutics Receives NIH CREATE Bio Award for Bladder and Bowel Therapy

2019-2020

  • Dignify Therapeutics Receives Five Additional NIH Awards for $2.5 Million in 2019-2020

2023

  • Dignify Therapeutics Receives NIH Award for preclinical and clinical development of a novel, on-demand, voiding therapy
  • Dignify Therapeutics and Aayam Therapeutics enter into licensing agreement for novel on-demand defecation drug – Agreement expands Dignify’s intellectual property portfolio

2024

  • Dignify Therapeutics Announces the Issuance of US Patent No. 10,086,034 for treatment of voiding dysfunction
  • Dignify Therapeutics awarded two new research grants from the National Institutes of Health (NIH)
  • Dignify Therapeutics Selected as a Praxis SCI Accelerate Company

Listen to the Interview with Co-Founder Ed Burgard, Ph.D.

Eva Garland Consulting CEO, Dr. Eva Garland, speaks with Dignify Therapeutics co-founder Dr. Ed Burgard. Ed provides insight on how EGC has helped guide their non-dilutive funding approach, wich started 10 years of consistent funding.